Please assess the completion status of the following clinical trial:

Trial Title: RCT of ChondroCelect® (in an ACI Procedure) vs Microfracture in the Repair of Cartilage Defects of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed patient informed consent~* Symptomatic cartilage single lesion of the femoral condyle~* Lesion on femoral condyle between 1 and 5 cm²~* Agree to participate actively in a strict rehabilitation protocol and follow-up programme~* Agree to only use paracetamol mono-or combination preparation (max 4g/d) and Non-Steroidal Anti Inflammatory Drugs (NSAIDS) during the study and to discontinue this medication 2 weeks before the baseline visit and the follow-up visits. The use of paracetamol mono-preparation (max 4g/d) is allowed up to one week before the baseline visit and the follow-up visits.~* Females of childbearing age should use a proven method to prevent pregnancy~Exclusion Criteria:~* Participation in concurrent trials~* Participation in previous trials within 3 months~* Subjects with hepatitis, HIV or syphilis~* Malignancy~* Alcohol or drug (medication) abuse~* Poor general health as judged by Investigator~* Clinically relevant second cartilage lesion on the patella~* Patellofemoral cartilage lesion~* Osteochondritis Dissecans (OCD) : recent OCD (within 1 year before baseline), depth of lesion \> 0.5cm, subchondral slerosis~* Advanced osteoarthritis (OA) : radiographic atlas of OA grade 2-3~* Known allergy to gentamicin or penicillins (or presence of multiple severe allergies)~* Complex ligamentous instability of the knee~* Meniscal transplant~* Meniscal suture with meniscal arrows (ipsilateral)~* Meniscus resection : if \< 1 yr before baseline - lateral meniscus resection or medial meniscus resection of more than 50%. If \> 1 yr before baseline - ipsilateral meniscus resection of more than 50%, controlateral meniscus resection of more than 50% if ipsilateral meniscus is not intact, combination of medial and lateral meniscus resection and one of both \> 50%.~* Varus or valgus malalignment of more than 5°~* Mosaicplasty~* Microfracture performed less than 1 yr before baseline~* Having received hyaluronic acid intra-articular injections in the affected knee within the last 6 months of baseline~* Taking specific OA drugs such as chondroïtin sulfate, diacerein, n-glucosamine, piascledine, capsaicin within 2 weeks of the baseline visit~* Corticosteroïd treatment by systemic or intra-articular route within the last month of baseline or intramuscular or oral corticosteroïds within the last 2 weeks of baseline~* Chronic use of anticoagulants~* Uncontrolled diabetes~* Any concomitant painful or disabling disease of the spine,hips or lower limbs that would interfere with evaluation of the afflicted knee~* Any clinically significant or symptomatic vascular or neurologic disorder of the lower extremities~* Any evidence of the following diseases in the target joint : septic arthritis, inflammatory joint disease, gout, recurrent episodes of pseudogout, Paget's disease of bone, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary osteochondromatosis, heritable disorders, collagen gene mutation~* Current diagnosis of osteomyelitis~* Liver enzymes (SGOT, SGPT, Alkaline Phosphatase) of more then two times the upper limit of normal or any other result that is clinically important according to the Investigator~* CRP \> 10 mg/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ChondroCelect (Type: EXPERIMENTAL): None
- Microfracture (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).